ZEPP files Form 144/A to sell 11,000 ADRs valued at $411,070

Rhea-AI Filing Summary

Zepp Health Corporation filed a Form 144/A notifying a proposed sale of 11,000 American Depositary Receipts (ADRs) representing its common stock, with an aggregate market value of $411,070 and approximately 7,173,522 shares outstanding. The proposed approximate date of sale is 09/04/2025 on the NYSE. The ADRs to be sold were acquired on 02/12/2018 through vesting of a restricted stock award from Zepp Health Corporation; the original grant comprised 25,000 shares and payment was recorded as vesting of a restricted share award on the same date. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information.

Insights

Securities Analyst

TL;DR Proposed sale of 11,000 ADRs valued at $411,070 is disclosed; transaction originates from a 2018 restricted stock vesting.

The filing documents a routine Section 144 notice for an insider or affiliate planning to sell 11,000 ADRs on the NYSE with an approximate sale date of 09/04/2025. The securities were acquired via vesting on 02/12/2018

From an investor-impact perspective, the size of the proposed sale ($411k) appears modest relative to typical market capitalizations for exchange-listed issuers, and the filer reports no sales in the prior three months. The Form contains the required attestation about absence of undisclosed material information. No earnings, debt, or operational data are provided in this filing.

Corporate Governance Expert

TL;DR This is a compliance disclosure of an intended sale under Rule 144 tied to vested restricted shares; it follows required attestation language.

The notice records the origin of the shares as a restricted stock vesting event in 2018 and states the filer has not sold related securities in the prior three months. The filing includes the standard Rule 10b5-1/attestation language, but does not indicate a trading plan adoption date. For governance reviews, the document is a routine disclosure and contains no additional corporate actions or governance changes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/08/2025 - 02:58 PM Learn about SEC filing dates

FAQ

What securities does Zepp Health (ZEPP) plan to sell according to this Form 144/A?

The filer proposes to sell 11,000 ADRs (American Depositary Receipts) representing common shares, with an aggregate market value of $411,070.

When is the approximate sale date listed on the Form 144/A for ZEPP?

The approximate date of sale is listed as 09/04/2025.

How and when were the securities being sold originally acquired?

The ADRs were acquired on 02/12/2018 through the vesting of a restricted stock award from Zepp Health Corporation; the original award amount was 25,000 shares.

Were any ZEPP securities sold by the filer in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.

On which exchange is the proposed sale to occur?

The proposed sale is identified for the NYSE.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK
Filer CCC
Previous Accession Number Of The Filing
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ADR (Common)	The Core Group Suite C 20/F 4-4A Des Voeux Road Central Hong Kong K3 Central	11000	411070.00	7173522	09/04/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADR (Common)	02/12/2018	Vesting of Restricted Stocks Award	Zepp Health Corporation			25000	02/12/2018	Vesting of Restricted Share Award

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Nothing to Report

144/A: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)